Bausch Health Companies Competitors

Bausch Health Companies (NYSE:BHC) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Bausch Health Companies and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Bausch Health Companies and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bausch Health Companies and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Bausch Health Companies presently has a consensus price target of $30.1818, suggesting a potential downside of 3.51%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential downside of 0.34%. Given Alexion Pharmaceuticals' higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than Bausch Health Companies.

Volatility & Risk

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Bausch Health Companies on 9 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Bausch Health Companies (NYSE:BHC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for BeiGene and Bausch Health Companies, as reported by MarketBeat.

BeiGene presently has a consensus target price of $308.1667, suggesting a potential downside of 6.54%. Bausch Health Companies has a consensus target price of $30.1818, suggesting a potential downside of 3.51%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, analysts clearly believe Bausch Health Companies is more favorable than BeiGene.

Volatility & Risk

BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares BeiGene and Bausch Health Companies' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares BeiGene and Bausch Health Companies' top-line revenue, earnings per share (EPS) and valuation.

BeiGene has higher earnings, but lower revenue than Bausch Health Companies. BeiGene is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bausch Health Companies beats BeiGene on 12 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Profitability

This table compares Bausch Health Companies and Genmab A/S's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bausch Health Companies and Genmab A/S, as reported by MarketBeat.

Bausch Health Companies presently has a consensus target price of $30.1818, indicating a potential downside of 3.51%. Genmab A/S has a consensus target price of $42.1429, indicating a potential upside of 25.13%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Bausch Health Companies.

Earnings & Valuation

This table compares Bausch Health Companies and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Genmab A/S has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 6.2% of Genmab A/S shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Bausch Health Companies beats Genmab A/S on 7 of the 13 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Bausch Health Companies (NYSE:BHC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Bausch Health Companies' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Horizon Therapeutics Public and Bausch Health Companies' top-line revenue, earnings per share and valuation.

Horizon Therapeutics Public has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Horizon Therapeutics Public and Bausch Health Companies, as provided by MarketBeat.com.

Horizon Therapeutics Public presently has a consensus price target of $101.8889, indicating a potential upside of 12.50%. Bausch Health Companies has a consensus price target of $30.1818, indicating a potential downside of 3.51%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Bausch Health Companies.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Horizon Therapeutics Public beats Bausch Health Companies on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 97.8% of Catalent shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Bausch Health Companies and Catalent's net margins, return on equity and return on assets.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Bausch Health Companies and Catalent, as provided by MarketBeat.com.

Bausch Health Companies presently has a consensus price target of $30.1818, suggesting a potential downside of 3.51%. Catalent has a consensus price target of $121.3750, suggesting a potential upside of 8.13%. Given Catalent's stronger consensus rating and higher possible upside, analysts clearly believe Catalent is more favorable than Bausch Health Companies.

Valuation & Earnings

This table compares Bausch Health Companies and Catalent's revenue, earnings per share and valuation.

Catalent has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Catalent beats Bausch Health Companies on 9 of the 13 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Bausch Health Companies (NYSE:BHC) are both large-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Bausch Health Companies, as reported by MarketBeat.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 10.33%. Bausch Health Companies has a consensus target price of $30.1818, suggesting a potential downside of 3.51%. Given Royalty Pharma's higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than Bausch Health Companies.

Profitability

This table compares Royalty Pharma and Bausch Health Companies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Royalty Pharma and Bausch Health Companies' gross revenue, earnings per share and valuation.

Royalty Pharma has higher earnings, but lower revenue than Bausch Health Companies.

Summary

Bausch Health Companies beats Royalty Pharma on 7 of the 9 factors compared between the two stocks.